… with Weight Loss Relative to Rosiglitazone
{"Image DocumentName": "\u2026 with Weight Loss Relative to Rosiglitazone", "Image ImageDescription": "Duration: 24 weeks Vilda vs rosi. Overall. BMI >35 kg/m2. n= BL (kg)= kg difference. Weight change from BL (kg) Weight Loss Relative to Rosiglitazone. This was a 24-week, double-blind, randomized, active-controlled, parallel-group, multicenter study to compare the efficacy and tolerability of vildagliptin (50 mg twice daily) and rosiglitazone (8 mg once daily).1. The primary intention-to-treat population comprised 697 patients (vildagliptin n=459; rosiglitazone n=238). No change in body weight was observed after 24 weeks of treatment with vildagliptin. This contrasted with an increase of 1.6 kg in the rosiglitazone treatment group; the between-treatment group difference was 1.9 kg (P <0.001). In the severely obese population (\u226535 kg/m2), a decrease in body weight was observed (\u22121.1 kg) with vildagliptin. At 24 weeks, the 2.8 kg difference in body weight between vildagliptin and rosiglitazone for the subgroup of severely obese patients was significantly in favor of vildagliptin (P <0.001). Weight gain is a common side effect of a thiazolidinedione (TZD). Vildagliptin has been shown to be as effective as a TZD but does not cause weight gain. Reference. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:     Vilda 50 mg twice daily. Rosi 8 mg once daily. BL=baseline; BMI=body mass index; rosi=rosiglitazone; vilda=vildagliptin  P <0.001 vs rosi. Primary intention-to-treat population. Rosenstock J, et al. Diabetes Care 2007; 20:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}